29 January 2023 - Eisai and Biogen announced today that an application for manufacturing and marketing approval for lecanemab, an anti-amyloid-β protofibril antibody, in Japan has been designated for priority review by the Japanese Ministry of Health, Labour and Welfare. 

Priority review in Japan is granted to new medicines recognised as having high medical utility for serious diseases, and once designated for priority review, the target total review period is shortened.

Read Biogen press release